menu search

Bayer says parkinson's stem cell therapy improves symptoms in initial trial

Bayer said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson's disease symptoms in an ea...

August 28, 2023, 2:03 am

Antero midstream: the path to a 10% yield

Antero Midstream Corporation is a high-yield stock with a current yield of 7.5% and potential for more than 10% yield in the future. AM is a midstream...

August 28, 2023, 2:03 am

Oil prices forecast: navigating china's economic woes, fed's hawkish tone

Crude Oil traders anticipating volatility amid China's economic slowdown and looming U.S. rate hikes....

August 28, 2023, 1:30 am

South korea clears path for hyundai motor strike -union

Hyundai Motor's unionised workers have won permission to go on strike, the union said on Monday, raising the probability of the company's first wage-r...

August 28, 2023, 1:00 am

Usdcad daily analysis – august 28, 2023

USDCAD has achieved a notable breakthrough, surpassing the significant resistance at 1.3603 and extending its upward trajectory from 1.3092 to reach a...

August 28, 2023, 12:50 am

Usdjpy daily analysis – august 28, 2023

USDJPY has made a significant breakthrough by surmounting the 146.55 resistance, signifying a resumption of the upward movement that began at 138.05. ...

August 28, 2023, 12:41 am

Gbpusd daily analysis – august 28, 2023

GBPUSD recently emerged from a period of sideways consolidation, confined within the 1.2615 to 1.2817 trading range. However, the currency pair has si...

August 28, 2023, 12:22 am

Us dollar outlook - mufg anticipate the usd will continue to see near-term gains

MUFG response to Friday's Jackson Hole speech from Federal Reserve Chair Powell. This summary is via the folks at eFX. For bank trade ideas, check out...

August 27, 2023, 10:52 pm

Bitcoin’s most faithful are staying put despite the crypto market’s recent weakness

Even after a big correction, which followed weeks of almost complete inactivity, and a new focus on real rates, bitcoin’s most ...

August 27, 2023, 4:59 pm

A bull market is coming: 2 exceptional stocks to buy right now

Finding the right stocks for your portfolio doesn't have to be rocket science, but persistence and pati...

August 27, 2023, 12:00 pm

High-potential marijuana stocks: top picks to watch before september 2023

The cannabis industry, once shrouded in stigma, has emerged as a thriving sector with remarkable growth potential. As September 2023 approaches, inves...

August 27, 2023, 11:00 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

From cash to clicks: the unstoppable rise of digital payments in india

By John patrick Lee, CFA, Product Manager India's audacious leap from a cash-centric economy to a pione...

August 27, 2023, 10:01 am

1 reason to sell zoom stock, and 1 reason to watch it and be patient

Zoom's most recent quarter was another lackluster report of little revenue growth. The company is still profitable by some metrics, but has a lot of w...

August 27, 2023, 9:30 am

Scholar rock: the market isn't enthusiastic despite decent clinical data

Scholar Rock Holding Corp. is developing a growth factor targeted therapy called apitegromab for Spinal Muscular Atrophy. Positive interim data from a...

August 27, 2023, 9:13 am

Love dividends? here are 3 great income stocks from the energy patch.

Exxon has an incredible streak of dividend growth despite oil being an inherently volatile sector. MPLX has steadily increased its monster payout....

August 27, 2023, 9:05 am


Search within

Pages Search Results: